sofosbuvir has been researched along with uridine in 8 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 5 (62.50) | 24.3611 |
2020's | 3 (37.50) | 2.80 |
Authors | Studies |
---|---|
Hartmann, MD; Heim, C; Hernandez Alvarez, B; Maiwald, S | 1 |
Guinan, M; Huang, N; Miller, GJ; Smith, M | 1 |
Basalious, EB; Karim, IA; Rezk, MR | 1 |
Brainard, DM; Curtis, C; Lasseter, K; Lawitz, E; Ling, KHJ; Marbury, T; Mathias, A; Mogalian, E; Moorehead, L; Murray, B; Osinusi, A; Perry, R | 1 |
Brainard, DM; Chen, G; Chen, H; Ding, Y; Li, X; Massetto, B; Niu, J; Shen, G; Zhang, H; Zhu, X | 1 |
Algharably, E; Budde, K; Duerr, M; Glander, P; Halleck, F; Hoffmann, F; Jaeger, C; Kreutz, R; Lisec, J; Schrezenmeier, E; Schrezenmeier, J | 1 |
Chen, G; Chen, H; Ding, Y; Li, X; Niu, J; Shen, Z; Zhang, H; Zhu, X | 1 |
Burger, DM; Colbers, A; Drenth, JPH; Freriksen, JJM; Greupink, R; Meijerhof, M; Russel, FGM; van Drongelen, J | 1 |
3 trial(s) available for sofosbuvir and uridine
Article | Year |
---|---|
Pharmacokinetics and Safety of Velpatasvir and Sofosbuvir/Velpatasvir in Subjects with Hepatic Impairment.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Carbamates; Drug Combinations; Drug Therapy, Combination; Female; Hepatic Insufficiency; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Uridine; Young Adult | 2018 |
Pharmacokinetics, Safety, and Tolerability of the Direct-acting Hepatitis C Antiviral Sofosbuvir in HealthyChineseSubjects.
Topics: Adult; Antiviral Agents; Asian People; Female; Healthy Volunteers; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir; Uridine; Young Adult | 2018 |
Pharmacokinetic Profile of a Generic Formulation of Sofosbuvir and Its Metabolite GS-331007 in Healthy Chinese Subjects.
Topics: Administration, Oral; Adult; Antiviral Agents; Area Under Curve; Dose-Response Relationship, Drug; Drugs, Generic; Female; Healthy Volunteers; Hepacivirus; Humans; Male; Metabolic Clearance Rate; Sofosbuvir; Uridine | 2019 |
5 other study(ies) available for sofosbuvir and uridine
Article | Year |
---|---|
Sweet and Blind Spots in E3 Ligase Ligand Space Revealed by a Thermophoresis-Based Assay.
Topics: | 2021 |
Design, chemical synthesis and antiviral evaluation of 2'-deoxy-2'-fluoro-2'-C-methyl-4'-thionucleosides.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Design; Hepacivirus; Microbial Sensitivity Tests; Molecular Structure; Structure-Activity Relationship; Thionucleosides; Virus Replication | 2022 |
Development of a sensitive UPLC-ESI-MS/MS method for quantification of sofosbuvir and its metabolite, GS-331007, in human plasma: Application to a bioequivalence study.
Topics: Area Under Curve; Calibration; Chromatography, High Pressure Liquid; Drug Stability; Healthy Volunteers; Humans; Limit of Detection; Plasma; Quality Control; Reproducibility of Results; Sofosbuvir; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Uridine | 2015 |
Pharmacokinetics of Daclatasvir, Sofosbuvir, and GS-331007 in a Prospective Cohort of Hepatitis C Virus-Positive Kidney Transplant Recipients.
Topics: Antiviral Agents; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Transplantation; Male; Middle Aged; Prospective Studies; Pyrrolidines; Sofosbuvir; Transplant Recipients; Uridine; Valine | 2019 |
Transfer of daclatasvir and sofosbuvir's main metabolite, GS-331007, across the human placenta ex vivo.
Topics: Antiviral Agents; Carbamates; Female; Hepatitis C; Humans; Imidazoles; Maternal-Fetal Exchange; Placenta; Pregnancy; Pregnancy Complications, Infectious; Pyrrolidines; Sofosbuvir; Uridine; Valine | 2020 |